Market Overview

Morgan Stanley Sees Execution Priced In For Becton, Dickinson and Co.

Related BDX
World Health Organization Issues Prequalification Of BD FACSPresto Near-Patient CD4 Counter System For HIV/AIDS Monitoring
Death Cross Stocks - The Coca-Cola Company, Crocs, Inc. & More

In a report published Tuesday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Becton, Dickinson and Co. (NYSE: BDX).

In the report, Morgan Stanley noted, “Recent meetings stressed confidence in ~5% sales growth and greater leverage in FY15. BD continues to express interest in larger deals, though <$1B is more likely in our view. Inversions are possible but limited targets suggest less probable. At 17x CY15 EPS, execution is priced in; remain EW.”

Becton, Dickinson and Co. closed on Monday at $118.30.

Latest Ratings for BDX

DateFirmActionFromTo
Aug 2014BarclaysMaintainsUnderweight
Aug 2014JP MorganMaintainsUnderweight
Jun 2014BarclaysMaintainsUnderweight

View More Analyst Ratings for BDX
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (BDX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters